H1 Launches “Strategy As A Service” Offering, Helps Life Sciences Companies Cut Time-To-Market In Half

By Bio-IT World Staff

September 21, 2018 | H1 launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.

The company’s new DaVinci service, which can help clients cut time-to-market in half, spans market landscape, validating strategy against an up-to-date, comprehensive picture of products and patient needs in the market; competitive Intelligence, anticipating market shifts with an insider’s view on the competition; and opportunity identification, zeroing in on the most promising targets across the unmet need, pathway, or technology by systematically evaluating the universe of potential targets.

The service is delivered jointly by H1 and partner Innovatively, a boutique life sciences consultancy based in New York City with deep expertise in healthcare business intelligence.

“It typically takes 10 years and $2.5 billion to bring a drug to market,” An Nguyen, CEO of Innovatively, said in a press release. “Our DaVinci service is designed to help biotech and life sciences companies leverage data to quickly narrow down their list of target opportunities from thousands to the top 10, at a fraction of the cost and time it would traditionally take. With that data in hand, our clients can then hit the ground running in the most promising markets with much less risk.”

Ben Kamens, Founder and CEO at Spring Discovery, which is accelerating the discovery of therapies for aging, was one of the first companies to leverage the DaVinci service, wrote in an official statement: “We’ve been working closely with An and team to build a curated database that helps us identify the right markets to target, and to understand those markets at an early stage in the process. In biotech, you have to make large and expensive choices early, and understanding the impact of those choices across dimensions - clinical, commercial, regulatory - is critical. DaVinci has played a big role helping us determine the best ways to apply our technology to start advancing therapeutics.”

There are typically 10 or more steps a life sciences or healthcare company has to take to bring a new drug to market, from coming up with a concept and obtaining grants to conducting clinical trials and analyzing the results. All of those steps have different repositories of data and it can cost millions and take years to collect and analyze all of that information.

H1’s DaVinci repurposes existing research data located in disparate sources all over the world to help healthcare companies accelerate their strategic planning and improve their strategies. It systematically evaluates therapeutic areas and identifies where a life science company may have an unfair advantage; helps expand the company’s development pipeline by identifying and evaluating potential assets to in-license; and supports new product planning with competitive intelligence.